TW200745112A - Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators - Google Patents

Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators

Info

Publication number
TW200745112A
TW200745112A TW095126927A TW95126927A TW200745112A TW 200745112 A TW200745112 A TW 200745112A TW 095126927 A TW095126927 A TW 095126927A TW 95126927 A TW95126927 A TW 95126927A TW 200745112 A TW200745112 A TW 200745112A
Authority
TW
Taiwan
Prior art keywords
receptor modulators
glutamate receptor
metabotropic glutamate
tricyclic benzimidazoles
compound
Prior art date
Application number
TW095126927A
Other languages
English (en)
Inventor
Methvin Isaac
Abdelmalik Slassi
Ian Egle
Fu-Peng Ma
Original Assignee
Astrazeneca Ab
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Nps Pharma Inc filed Critical Astrazeneca Ab
Publication of TW200745112A publication Critical patent/TW200745112A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095126927A 2005-08-05 2006-07-24 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators TW200745112A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70547105P 2005-08-05 2005-08-05

Publications (1)

Publication Number Publication Date
TW200745112A true TW200745112A (en) 2007-12-16

Family

ID=37607094

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095126927A TW200745112A (en) 2005-08-05 2006-07-24 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators

Country Status (17)

Country Link
US (2) US20070032469A1 (zh)
EP (1) EP1912989A2 (zh)
JP (1) JP2009503069A (zh)
KR (1) KR20080035576A (zh)
CN (1) CN101268077A (zh)
AR (1) AR055100A1 (zh)
AU (1) AU2006279034A1 (zh)
BR (1) BRPI0614168A2 (zh)
CA (1) CA2616020A1 (zh)
EC (1) ECSP088128A (zh)
IL (1) IL188809A0 (zh)
MX (1) MX2008001152A (zh)
NO (1) NO20080475L (zh)
RU (1) RU2008101923A (zh)
TW (1) TW200745112A (zh)
UY (1) UY29710A1 (zh)
WO (1) WO2007018998A2 (zh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP1963268B1 (en) * 2005-12-07 2010-12-01 NSAB, Filial af NeuroSearch Sweden AB, Sverige Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2150244A1 (en) * 2007-04-23 2010-02-10 House Ear Institute Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
EP2205565B1 (en) 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
MX2010005110A (es) * 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
AU2009246626A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
WO2009140166A2 (en) * 2008-05-15 2009-11-19 Merck & Co., Inc. Oxazolobenzimidazole derivatives
NZ588715A (en) * 2008-05-29 2012-11-30 Albany Molecular Res Inc 5-ht3 receptor modulators, methods of making, and use thereof
EP2303019A4 (en) * 2008-06-25 2013-07-17 Bermans S Iskandar (6S) -5-METHYLTETRAHYDROFOLIC ACID FOR THE TREATMENT OF TISSUE INJURIES
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
AU2009296931A1 (en) * 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のための化合物
GB201220157D0 (en) * 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
CN102964292A (zh) * 2012-11-26 2013-03-13 盛世泰科生物医药技术(苏州)有限公司 4-(2-(三氟甲氧基)苯基)哌啶的合成
SG10201707487VA (en) 2013-03-15 2017-10-30 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR101672096B1 (ko) * 2013-09-30 2016-11-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015154047A1 (en) * 2014-04-03 2015-10-08 Restorgenex Corporation Novel methods
SG11201608843TA (en) 2014-04-23 2016-11-29 Incyte Corp 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
WO2015174511A1 (ja) 2014-05-16 2015-11-19 塩野義製薬株式会社 Hiv複製阻害作用を有する3環性複素環誘導体
WO2016044130A1 (en) * 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
WO2016194806A1 (ja) * 2015-05-29 2016-12-08 塩野義製薬株式会社 Hiv複製阻害作用を有する含窒素3環性誘導体
EP3347361B1 (en) 2015-09-08 2020-08-05 H. Hoffnabb-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
KR20180053386A (ko) 2015-09-17 2018-05-21 마빈 제이. 밀러 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
IL263824B2 (en) 2016-06-20 2023-10-01 Incyte Corp Crystals in solid form in the presence of an inhibitor
MX369307B (es) 2016-08-19 2019-11-05 Gilead Sciences Inc Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
KR20210025016A (ko) * 2018-06-28 2021-03-08 지앙수 헨그루이 메디슨 컴퍼니 리미티드 접합 삼중고리형 헤테로사이클 화합물과 그 치료 용도
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
JP2022511540A (ja) * 2018-12-14 2022-01-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Stingアゴニストとしての三環式化合物、ならびにその調製方法および医薬用途
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
CN113631535B (zh) * 2019-03-11 2024-04-12 协同医药发展有限公司 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN116283758B (zh) * 2023-03-30 2024-05-24 安徽工业大学 一种喹啉合成n-甲酰基四氢喹啉的方法及产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU2001282267A1 (en) * 2000-08-08 2002-02-18 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
AU3652102A (en) * 2000-12-01 2002-06-11 Guilford Pharm Inc Compounds and their uses

Also Published As

Publication number Publication date
CA2616020A1 (en) 2007-02-15
IL188809A0 (en) 2008-08-07
EP1912989A2 (en) 2008-04-23
KR20080035576A (ko) 2008-04-23
US20080318999A1 (en) 2008-12-25
NO20080475L (no) 2008-04-15
MX2008001152A (es) 2008-04-02
WO2007018998A3 (en) 2007-05-03
US20070032469A1 (en) 2007-02-08
RU2008101923A (ru) 2009-09-10
AR055100A1 (es) 2007-08-08
WO2007018998A2 (en) 2007-02-15
UY29710A1 (es) 2007-02-28
ECSP088128A (es) 2008-02-20
JP2009503069A (ja) 2009-01-29
CN101268077A (zh) 2008-09-17
AU2006279034A1 (en) 2007-02-15
BRPI0614168A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
TW200745112A (en) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
HK1095138A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UA108070C2 (uk) ПОХІДНІ 1,2,4-ТРИАЗОЛО[4,3-а]ПІРИДИНУ ТА ЇХ ЗАСТОСУВАННЯ ЯК ПОЗИТИВНИХ АЛОСТЕРИЧНИХ МОДУЛЯТОРІВ РЕЦЕПТОРІВ mGluR2
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
MX2009012749A (es) Compuestos heterociclicos como moduladores positivos del receptor de glutamato metabotropico 2 (receptor mglu2).
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
MX2011011963A (es) Derivados de 7-aril-1,2,4-triazolo[4,3-a]piridina y uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
MY153912A (en) 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
MX2008002065A (es) Derivados de pirazola como agentes terapeuticos.
TW200734324A (en) Therapeutic agents
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie